Skip to Content

Join the 'Rytary' group to help and get support from people like you.

Rytary News

Inhaled Version of Parkinson's Drug May Help Keep Symptoms at Bay

Posted 12 Oct 2016 by Drugs.com

WEDNESDAY, Oct. 12, 2016 – An inhaled version of the Parkinson's drug levodopa can help when patients experience symptoms between doses of the pill form of the medication, a new, small study finds. Levodopa can control the tremors, rigidity and difficulty maintaining balance and coordination associated with Parkinson's disease. However, within two years, as many as half of all patients have rapid and unexpected loss of motor control during "off" periods, when the drug wears off between doses, the researchers explained. "Off periods are considered one of the greatest unmet medical needs in the treatment of Parkinson's, and typically increase in frequency during the course of the disease," said lead researcher Michael Lipp. He is vice president of pharmaceutical development and technical operations at Acorda Therapeutics, the drug's maker and funder of the study. Inhaled levodopa could ... Read more

Related support groups: Parkinson's Disease, Sinemet, Levodopa, Carbidopa/Levodopa, Stalevo, Sinemet CR, Parkinsonian Tremor, Rytary, Stalevo 100, Parkinsonism, Parcopa, Carbidopa/Entacapone/Levodopa, Stalevo 200, Stalevo 150, Dopar, Stalevo 50, Stalevo 125, Parkinson's Disease Psychosis, Atamet, Larodopa

Study Questions Use of Physical Therapy for Early Parkinson's

Posted 19 Jan 2016 by Drugs.com

TUESDAY, Jan. 19, 2016 – Physical therapy might not benefit people with mild-to-moderate Parkinson's disease, a new study suggests. Parkinson's disease is a movement disorder that interferes with the ability to do daily tasks. Typically, physical therapy is used in the later stages of the disease, but this study assessed its effectiveness in earlier stages. Researchers randomly assigned 762 patients with mild-to-moderate Parkinson's to either physical therapy and occupational therapy, or a "control" group with no therapy. Over eight weeks, the patients in the therapy group did about four 58-minute sessions. After three months, there was no difference between the therapy group and the control group in the ability to do daily tasks, the study found. The results were published online Jan. 19 in the journal JAMA Neurology. It's possible that mild-to-moderate Parkinson's disease may not ... Read more

Related support groups: Parkinson's Disease, Sinemet, Levodopa, Carbidopa/Levodopa, Stalevo, Sinemet CR, Parkinsonian Tremor, Rytary, Stalevo 100, Parkinsonism, Parcopa, Carbidopa/Entacapone/Levodopa, Stalevo 200, Stalevo 150, Dopar, Stalevo 50, Stalevo 125, Atamet, Larodopa, Duopa

New Clues to Easing Side Effects From Parkinson's Drug

Posted 18 Nov 2015 by Drugs.com

WEDNESDAY, Nov. 18, 2015 – The drug levodopa is a leading treatment for Parkinson's disease, but for most patients the medication also brings debilitating side effects. Now, scientists say animal studies are pointing to a compound that might reduce those unwanted effects. "If clinical trials confirm our preliminary findings, the eventual drug developed could make a significant improvement in the quality of life for people with Parkinson's disease," lead researcher D. James Surmeier, chair of physiology at Northwestern University School of Medicine in Chicago, said in a university news release. According to the researchers, Parkinson's disease affects more than one million Americans, and that number is expected to double by 2030. Levodopa is widely used to treat the stiffness, tremors and poor muscle control caused by the illness. But the drug can also trigger uncontrolled movement – ... Read more

Related support groups: Parkinson's Disease, Sinemet, Levodopa, Carbidopa/Levodopa, Stalevo, Sinemet CR, Parkinsonian Tremor, Rytary, Stalevo 100, Parkinsonism, Parcopa, Carbidopa/Entacapone/Levodopa, Stalevo 200, Stalevo 150, Dopar, Stalevo 50, Stalevo 125, Atamet, Larodopa, Duopa

Parkinson's Drug Shows Promise Against Macular Degeneration

Posted 12 Nov 2015 by Drugs.com

THURSDAY, Nov. 12, 2015 – A common Parkinson's disease medication might hold potential for preventing or treating macular degeneration, the leading cause of vision loss in the elderly, new research suggests. At this stage, no one is recommending that patients take the drug, levodopa (L-dopa), to thwart eye disease. But the findings are intriguing, researchers said. "Patients taking L-dopa for any reason are much less likely to develop age-related macular degeneration. If they do, they develop the disease much later in life than those not taking L-dopa," said study lead author Brian McKay, an associate professor of ophthalmology and vision science at the University of Arizona. However, the study doesn't actually prove that levodopa causes a lower incidence of age-related macular degeneration. It only uncovered an association between the two. Age-related macular degeneration affects ... Read more

Related support groups: Parkinson's Disease, Sinemet, Macular Degeneration, Levodopa, Carbidopa/Levodopa, Stalevo, Sinemet CR, Diagnosis and Investigation, Parkinsonian Tremor, Rytary, Stalevo 100, Parkinsonism, Parcopa, Carbidopa/Entacapone/Levodopa, Stalevo 200, Stalevo 75, Stalevo 150, Dopar, Stalevo 50, Stalevo 125

Exercise Benefits People With Parkinson's Disease: Study

Posted 24 Jun 2015 by Drugs.com

WEDNESDAY, June 24, 2015 – Parkinson's disease patients who begin regular exercise earlier have a much slower decline in quality of life than those who start exercising later, a new study finds. National Parkinson Foundation (NPF) researchers looked at information from nearly 3,000 patients. More than 1,300 reported doing little regular exercise before taking part in the study. Over two years, 500 of the inactive patients began to exercise more than 2.5 hours a week. The researchers compared patients who exercised regularly for the entire two years to people who were inactive at the start of the study, but then began a regular exercise routine. The study didn't note the type of workouts, just the total amount of exercise. After two years, scores on a questionnaire that measured the impact of Parkinson's on daily life in a number of areas – including mood, movement and social ... Read more

Related support groups: Benadryl, Parkinson's Disease, Diphenhydramine, Mirapex, Requip, Ropinirole, Sinemet, Pramipexole, Cogentin, Levodopa, Azilect, Carbidopa, Emsam, Bromocriptine, Cabergoline, Benztropine, Amantadine, Benadryl Allergy, Selegiline, Neupro

Ex-Baseball Star Kirk Gibson Has Parkinson's Disease

Posted 28 Apr 2015 by Drugs.com

TUESDAY, April 28, 2015 – Kirk Gibson, who played 17 seasons of Major League Baseball and is perhaps best known for a dramatic pinch-hit, ninth inning home run to win a World Series game in 1988, said Tuesday he has Parkinson's disease. Gibson, 57, a Michigan native who played 12 seasons with the Detroit Tigers, said in a statement that "I have faced many different obstacles in my life, and have always maintained a strong belief that no matter the circumstances, I could overcome those obstacles. "While this diagnosis poses a new kind of challenge for me, I intend to stay true to my beliefs," he added. "With the support of my family and friends, I will meet this challenge with the same determination and unwavering intensity that I have displayed in all of my endeavors in life. I look forward to being back at the ballpark as soon as possible." According to the U.S. National Institutes of ... Read more

Related support groups: Benadryl, Parkinson's Disease, Diphenhydramine, Mirapex, Requip, Ropinirole, Sinemet, Pramipexole, Cogentin, Levodopa, Azilect, Carbidopa, Emsam, Bromocriptine, Cabergoline, Benztropine, Amantadine, Benadryl Allergy, Selegiline, Neupro

Ask a Question

Further Information

Related Condition Support Groups

Parkinson's Disease

Rytary Patient Information at Drugs.com